Pembrolizumab in Combination with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Clinical Evidence, Regulatory Approval and Therapeutic Implications
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Primary peritoneal carcinoma, fallopian tube cancer, and platinum-resistant epithelial ovarian cancer are aggressive cancers with few treatment choices and a dismal prognosis. In a variety of solid malignancies, immune checkpoint medications that target the programmed death receptor-1 (PD-1) have demonstrated encouraging activity. Objectives: To examine the clinical effectiveness, safety, and therapeutic implications of pembrolizumab in combination with paclitaxel, with or without bevacizumab, for platinum-resistant ovarian cancers that express programmed death-ligand 1 (PD-L1). This approval was recently made by the US Food and Drug Administration (FDA). Methods: Reviewed KEYNOTE-B96 (NCT05116189) clinical trial data, prescription information, and regulatory announcements. Progress-free survival (PFS) and overall survival (OS), as determined by the RECIST v1.1 criteria, were key effectiveness goals. Results: PFS was 8.3 months in the pembrolizumab arm and 7.2 months in the placebo arm for patients with PD-L1 combination positive score (CPS) ≥1 (HR 0.72; p = 0.0014). 18.2 months and 14.0 months, respectively, were the median OS (HR 0.76; p = 0.0053). The safety profile aligned with immune-related side effects linked to PD-1 inhibitors that have been documented before. Conclusion: The treatment of platinum-resistant ovarian tumors has advanced clinically with the approval of pembrolizumab in combination therapy. PD-L1 CPS-based biomarker-driven patient selection improves precision oncology methods and could lead to better survival rates in this high-risk group.
Fields of Study & Subjects
Ovarian cancer diagnosis and treatment
Cancer Immunotherapy and Biomarkers
PARP inhibition in cancer therapy
Publication details
- Journal / source
- Scientific Journal of Genetics and Gene Therapy
- Volume
- 12
- Issue
- 1
- Pages
- 001–003
- Publication date
- 1 January 2026
- Language
- EN